A. Dangelo
3 Papers
1 Citations
A. Dangelo is an academic researcher. The author has contributed to research in topics: Quality assurance & Peptidomimetic. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Proceedings to the 25th International Workshop"What Comes Beyond the Standard Models", July 4 -- July 10, 2022, Bled, Slovenia
Roberto Bernabei,P. Belli,Andrea Bussolotti,V. Caracciolo,R. Cerulli,N. Ferrari,A. Leoncini,V. Merlo,F. Montecchia,F. Cappella,A. Dangelo,A. Incicchitti,A. Mattei,C. J. Dai,X. H. Ma,Xiangdong Sheng,Z. P. Ye,Vitaly Beylin,Loriano Bonora,Samuel J. Brodsky,Paul H. Frampton,AK Ghoshal,Giulia Lambiase,Sulakshana Pal,Araujo Saa Alvaro Paul,S. Porey,Albino Hernandez-Galeana,M. Yu. Khlopov,Orchidea Maria Lecian,Felix M. Lev,N. S. Mankoc Borstnik,Rabindra N. Mohapatra,Holger Bech Nielsen,C.D. Froggatt,Keiichi Nagao,Guy F. de Teramond,Konstantin Zioutas,Vassilis Anastassopoulos,A. Argiriou,Giovanni Cantatore,Sevgi Pakiş Çetin,A. Gardikiotis,Marin Karuza,A. Kryemadhi,M. Maroudas,A. Mastronikolis,Kaan Ozbozduman,Yannis K. Semertzidis,M. Tsagri,I. Tsagris,V. Monakhov,Masao Ninomiya,Paolo Salucci,Elizabeth Dmitrieff +53 more
- 29 Mar 2023
TL;DR: The ''What comes beyond the standard models'' meeting as discussed by the authors covered a broad series of subjects, including a broad range of approaches to the problem of "what comes beyond standard models".
Impact of Quality Assurance and Feedback on Radiotherapy Prescribing Practices: A Randomized Controlled Trial
A. Dangelo,G. Arbour,Theodora A. Koulis,Jeremy Hamm,Caroline Speers,Emily Yurkowski,Scott Matlock,Adrienne Stedford,Scott Tyldesley,Caroline Lohrisch,Alan Nichol,Robert Olson +11 more
TL;DR: In this paper , the authors identify the impact of a simple CA&F intervention on prescribing practices across six BC Cancer Centers by investigating four clinical scenarios: (1) women <50 years old with invasive breast cancer post partial mastectomy who receive surgical cavity RT boost vs not, (2) patients with 1-3 positive lymph nodes receiving regional RT vs not; (3) women >70 years old having T1N0 breast cancer omitting whole breast RT and (4) all women who received local or locoregional radiotherapy who are prescribed 16 versus 25 fractions of RT.